PL367267A1 - Antineoplastic combinations - Google Patents

Antineoplastic combinations

Info

Publication number
PL367267A1
PL367267A1 PL02367267A PL36726702A PL367267A1 PL 367267 A1 PL367267 A1 PL 367267A1 PL 02367267 A PL02367267 A PL 02367267A PL 36726702 A PL36726702 A PL 36726702A PL 367267 A1 PL367267 A1 PL 367267A1
Authority
PL
Poland
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
PL02367267A
Other languages
English (en)
Polish (pl)
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of PL367267A1 publication Critical patent/PL367267A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02367267A 2001-06-01 2002-05-29 Antineoplastic combinations PL367267A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
PL367267A1 true PL367267A1 (en) 2005-02-21

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367267A PL367267A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (enExample)
JP (1) JP2004532883A (enExample)
KR (1) KR100875611B1 (enExample)
CN (1) CN100496485C (enExample)
AU (2) AU2002259309B2 (enExample)
BR (1) BR0210101A (enExample)
CA (1) CA2447732A1 (enExample)
CO (1) CO5540294A2 (enExample)
EA (1) EA007530B1 (enExample)
HU (1) HUP0400006A2 (enExample)
IL (1) IL158800A0 (enExample)
MX (1) MXPA03010907A (enExample)
NO (1) NO20035317L (enExample)
NZ (1) NZ529877A (enExample)
PL (1) PL367267A1 (enExample)
SG (1) SG153647A1 (enExample)
WO (1) WO2002098416A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) * 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
LT2481402T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
SG43072A1 (en) * 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu

Also Published As

Publication number Publication date
AU2008202690A1 (en) 2008-07-10
CO5540294A2 (es) 2005-07-29
NZ529877A (en) 2006-08-31
EA007530B1 (ru) 2006-10-27
NO20035317L (no) 2003-12-22
BR0210101A (pt) 2004-06-08
AU2002259309B2 (en) 2008-05-01
WO2002098416A2 (en) 2002-12-12
EP1392286A2 (en) 2004-03-03
EA200301319A1 (ru) 2004-04-29
CN1646120A (zh) 2005-07-27
SG153647A1 (en) 2009-07-29
KR20040025923A (ko) 2004-03-26
JP2004532883A (ja) 2004-10-28
KR100875611B1 (ko) 2008-12-24
NO20035317D0 (no) 2003-11-28
MXPA03010907A (es) 2004-02-17
CA2447732A1 (en) 2002-12-12
IL158800A0 (en) 2004-05-12
WO2002098416A3 (en) 2003-03-13
HUP0400006A2 (hu) 2004-04-28
CN100496485C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
IL159859A0 (en) Antineoplastic combinations
DE60217162D1 (en) Tetrafluorethen-perfluorbutylethen-copolymer
DE50202400D1 (en) Baw-resonator
DE60217478D1 (en) Sychrongleichrichter
DE60231477D1 (en) Imidazolderivate
IL160851A0 (en) Thiopene-and thiazolesulfonamides as antineoplastic agents
DE60141362D1 (en) Ösophagus-stoma-knopf
DE50202633D1 (en) Ophthalmoskop
DE60218514D1 (en) Polyolefin-kunststoffrohre
IL158800A0 (en) Antineoplastic combinations
ZA200603888B (en) Antineoplastic combinations
EP1417203A4 (en) S-6-HYDROXY-BUSPIRONE
DE60226167D1 (en) Computersystem-e/a-knoten
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
DE50214962D1 (en) Heterocyclylarylsulfonamide
EP1355643A4 (en) EPOXYVIBSANIN B
AU2001100134A4 (en) Enviro-trap
GB0118576D0 (en) Quadrail supertrain
GB0117479D0 (en) Jetters
CA93646S (en) Fauteuil
CA93126S (en) Titlt-latch
HK1060846A (en) Antineoplastic combinations
GB0116610D0 (en) Grippalite
GB0112187D0 (en) Fedorak-a-lope
GB0110509D0 (en) Klinette

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)